Determined to take the company’s next-generation engineered cell therapies to the next level, BlueRock Therapeutics is teaming up with Senti Biosciences with futuristic medicines in mind.
Recently published research in the journal Nature Genetics found significant insight into this question: Why does a patient with an autoimmune disease become a type 1 diabetic rather than have rheumatoid arthritis?
